Özlem Okutman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Özlem Okutman has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Stéphane Viville
Laboratoire de Diagnostic Génétique, Unité de Génétique de L’infertilité (UF3472), Hôpitaux Universitaires de Strasbourg, Strasbourg, France
16 shared publications - Jean Muller
Laboratoire de Génétique Médicale LGM, Institut de Génétique Médicale d’Alsace (IGMA), INSERM UMR 1112, University of Strasbourg, Strasbourg, France
7 shared publications - Willem Verpoest
Department of Gynaecology and Reproductive Medicine, Utrecht University, Utrecht University Medical Centre (UMCU) , Utrecht
4 shared publications - Annelore Van Der Kelen
Centre for Medical Genetics, Research Group Genetics, Reproduction and Development (GRAD), Clinical Sciences, Universitair Ziekenhuis Brussel (UZ Brussel) - Vrije Universiteit Brussel (VUB) , Brussels
3 shared publications - Joris A. Veltman
Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom
3 shared publications - Karen Sermon
Research Group Genetics Reproduction and Development (GRAD), Vrije Universiteit Brussel , Brussels
3 shared publications
Latest Publications
- 9 June 2026
- Published by Academician Publishing
- p. 637-644
IVF Embriyoloji, Androloji Laboratuvarında Kalite Kontrol Nasıl Yapılmalı ?
- 9 June 2026
- Published by Academician Publishing
- p. 637-644
IVF Embriyoloji, Androloji Laboratuvarında Kalite Kontrol Nasıl Yapılmalı ?
- Open Access
- 1 June 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (7) , 1207-1219
A comprehensive review for defining cut-off values of oocyte, zygote, and embryo maturation arrest (OZEMA) due to maternal-effect genes: towards the establishment of clinical criteria
STUDY QUESTION: Which clinical definition of oocyte, zygote, and embryo maturation arrest (OZEMA) merits genetic investigation? SUMMARY ANSWER: The diagnosis OZEMA is considered when: only two mature oocytes are obtained from six cumulus–oocyte complexes (COCs), only one zygote is obtained from six metaphase II oocytes (MIIs), or no blastocysts are obtained from six two-pronuclei zygotes (2PNs). WHAT IS KNOWN ALREADY: OZEMA is a cover term for various defects, including oocyte abnormalities, fertilization failure, cleavage arrest, and abnormal embryo development, often associated with specific genetic variants. While some variants in specific genes are associated with distinct phenotypes, others commonly display variable expressivity across cycles and patients. Currently, there are no standardized cut-off values defining the OZEMA disorder. STUDY DESIGN, SIZE, DURATION: This is a pooled secondary analysis of aggregated data extracted from published studies. A PubMed search was conducted to identify peer-reviewed original studies in the human reporting genetically confirmed cases of OZEMA. Studies were included if patients had displayed OZEMA in at least two medically assisted reproduction (MAR) cycles. In total, clinical and genetic data were extracted from 132 publications, including 521 patients and 39 genes. PARTICIPANTS/MATERIALS, SETTING, METHODS: Clinical phenotypes from 132 publications were classified into oocyte maturation arrest (OMA), zona pellucida abnormality (ZPA), fertilization failure (FF), zygote arrest (ZA), early embryo arrest (EEA), mixed phenotypes, and other abnormalities. Data at both cycle and patient levels were evaluated using ratios corresponding to key developmental milestones (ratio of MII/COC, 2PN/MII, cleaved embryos/2PN, blastocysts/2PN). These ratios were compared with the expected values Vienna Consensus binomial modeling to assess whether the observed proportions were significantly lower than the established competency thresholds (P < 0.05). MAIN RESULTS AND THE ROLE OF CHANCE: This review identified 39 OZEMA-associated genes. Analysis of 668 cycles from 253 patients carrying variants in 35 genes showed abnormal developmental outcomes in 93%, based on binomial modeling. Reliable diagnosis of OZEMA requires a sufficient number of COCs, MIIs, or 2PNs to distinguish true developmental impairment from normal biological variation. When these minimal thresholds are not reached, statistical power is insufficient to reliably confirm developmental arrest. Based on our findings, OZEMA is diagnosed when only two or fewer mature oocytes form from six COCs, one or no zygote forms from six MIIs, or no blastocysts form from six 2PNs. LIMITATIONS, REASONS FOR CAUTION: This study is limited by its retrospective design and reliance exclusively on published data from women selected for poor IVF outcomes and the presence of variants in candidate OZEMA genes, which may introduce publication bias and reporting heterogeneity. Therefore, this study does not report on genetic yield from women with normal IVF outcomes. Variability in clinical protocols and genetic testing methods, limited ancestral diversity, and missing data across studies could contribute to confounding factors. WIDER IMPLICATIONS OF THE FINDINGS: This study is an important step toward understanding the clinical and genetic spectrum of OZEMA, highlighting the variability of and overlap between affected subphenotypes. Establishing cut-off values against consensus oocyte and embryo developmental competency levels provides a benchmark for more accurate classification. Importantly, this represents the most comprehensive analysis of published OZEMA cases with genetic variants to date, strengthening the reliability of the proposed clinical thresholds. These findings may guide personalized treatment strategies and genetic counseling, ultimately improving outcomes in MAR. STUDY FUNDING/COMPETING INTEREST(S): No funding was received for this study. The authors declare no competing interests. REGISTRATION NUMBER: Not applicable.
- 1 June 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (7) , 1207-1219
Open AccessA comprehensive review for defining cut-off values of oocyte, zygote, and embryo maturation arrest (OZEMA) due to maternal-effect genes: towards the establishment of clinical criteria
STUDY QUESTION: Which clinical definition of oocyte, zygote, and embryo maturation arrest (OZEMA) merits genetic investigation? SUMMARY ANSWER: The diagnosis OZEMA is considered when: only two mature oocytes are obtained from six cumulus–oocyte complexes (COCs), only one zygote is obtained from six metaphase II oocytes (MIIs), or no blastocysts are obtained from six two-pronuclei zygotes (2PNs). WHAT IS KNOWN ALREADY: OZEMA is a cover term for various defects, including oocyte abnormalities, fertilization failure, cleavage arrest, and abnormal embryo development, often associated with specific genetic variants. While some variants in specific genes are associated with distinct phenotypes, others commonly display variable expressivity across cycles and patients. Currently, there are no standardized cut-off values defining the OZEMA disorder. STUDY DESIGN, SIZE, DURATION: This is a pooled secondary analysis of aggregated data extracted from published studies. A PubMed search was conducted to identify peer-reviewed original studies in the human reporting genetically confirmed cases of OZEMA. Studies were included if patients had displayed OZEMA in at least two medically assisted reproduction (MAR) cycles. In total, clinical and genetic data were extracted from 132 publications, including 521 patients and 39 genes. PARTICIPANTS/MATERIALS, SETTING, METHODS: Clinical phenotypes from 132 publications were classified into oocyte maturation arrest (OMA), zona pellucida abnormality (ZPA), fertilization failure (FF), zygote arrest (ZA), early embryo arrest (EEA), mixed phenotypes, and other abnormalities. Data at both cycle and patient levels were evaluated using ratios corresponding to key developmental milestones (ratio of MII/COC, 2PN/MII, cleaved embryos/2PN, blastocysts/2PN). These ratios were compared with the expected values Vienna Consensus binomial modeling to assess whether the observed proportions were significantly lower than the established competency thresholds (P < 0.05). MAIN RESULTS AND THE ROLE OF CHANCE: This review identified 39 OZEMA-associated genes. Analysis of 668 cycles from 253 patients carrying variants in 35 genes showed abnormal developmental outcomes in 93%, based on binomial modeling. Reliable diagnosis of OZEMA requires a sufficient number of COCs, MIIs, or 2PNs to distinguish true developmental impairment from normal biological variation. When these minimal thresholds are not reached, statistical power is insufficient to reliably confirm developmental arrest. Based on our findings, OZEMA is diagnosed when only two or fewer mature oocytes form from six COCs, one or no zygote forms from six MIIs, or no blastocysts form from six 2PNs. LIMITATIONS, REASONS FOR CAUTION: This study is limited by its retrospective design and reliance exclusively on published data from women selected for poor IVF outcomes and the presence of variants in candidate OZEMA genes, which may introduce publication bias and reporting heterogeneity. Therefore, this study does not report on genetic yield from women with normal IVF outcomes. Variability in clinical protocols and genetic testing methods, limited ancestral diversity, and missing data across studies could contribute to confounding factors. WIDER IMPLICATIONS OF THE FINDINGS: This study is an important step toward understanding the clinical and genetic spectrum of OZEMA, highlighting the variability of and overlap between affected subphenotypes. Establishing cut-off values against consensus oocyte and embryo developmental competency levels provides a benchmark for more accurate classification. Importantly, this represents the most comprehensive analysis of published OZEMA cases with genetic variants to date, strengthening the reliability of the proposed clinical thresholds. These findings may guide personalized treatment strategies and genetic counseling, ultimately improving outcomes in MAR. STUDY FUNDING/COMPETING INTEREST(S): No funding was received for this study. The authors declare no competing interests. REGISTRATION NUMBER: Not applicable.
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Genetics of male infertility : genes implicated in non-obstructive azoospermia and severe oligozoospermia
Génétique de l'infertilité masculine : identification de gènes impliqués dans l'azoospermie non obstructive et oligozoospermie sévère: Parmi les couples avec un projet parental, le facteur masculin d’infertilité est responsable d’environ 20%. Malgré de longues années d’activités d’assistance médicale à la procréation, un nombre important de cas reste idiopathiques. Considérant le nombre élevé des gènes potentiellement impliqués dans la gamétogenèse, il est fort probable que la majorité des formes ‘idiopathiques’ sont d’origine génétique. Dans l'étude présente, nous avons d’identifier deux nouveaux gènes impliqués dans une infertilité masculine. Nos données suggèrent que la mutation dans TEX15 puisse corréler avec une diminution du nombre de spermatozoïdes au fil du temps. Un test diagnostique identifiant la mutation chez un patient pourrait fournir une indication d’organiser au plus tôt une cryopréservation du sperme. On a aussi identifié MAGEB4 liées à l’X comme un nouveau gène impliqué dans une infertilité masculine héritée. Cette étude fournit le premier indice sur la fonction physiologique d'une protéine MAGE.
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Genetics of male infertility : genes implicated in non-obstructive azoospermia and severe oligozoospermia
Génétique de l'infertilité masculine : identification de gènes impliqués dans l'azoospermie non obstructive et oligozoospermie sévère: Parmi les couples avec un projet parental, le facteur masculin d’infertilité est responsable d’environ 20%. Malgré de longues années d’activités d’assistance médicale à la procréation, un nombre important de cas reste idiopathiques. Considérant le nombre élevé des gènes potentiellement impliqués dans la gamétogenèse, il est fort probable que la majorité des formes ‘idiopathiques’ sont d’origine génétique. Dans l'étude présente, nous avons d’identifier deux nouveaux gènes impliqués dans une infertilité masculine. Nos données suggèrent que la mutation dans TEX15 puisse corréler avec une diminution du nombre de spermatozoïdes au fil du temps. Un test diagnostique identifiant la mutation chez un patient pourrait fournir une indication d’organiser au plus tôt une cryopréservation du sperme. On a aussi identifié MAGEB4 liées à l’X comme un nouveau gène impliqué dans une infertilité masculine héritée. Cette étude fournit le premier indice sur la fonction physiologique d'une protéine MAGE.
- 5 February 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (4) , 1209-1218
Disruption of meiotic double-strand break dynamics provokes germline human infertility in both sexes
Purpose To explore genetic basis leading to meiotic disruption in human gametogenesis via exome sequencing. Methods This study included three consanguineous families with well-defined infertility phenotypes. Exome sequencing was performed for the index case in family 1 and for the trio (index with parents) in the other two families. Sanger sequencing was used for confirmation and family segregation analysis. Results Exome sequencing revealed homozygous loss-of-function variations in SPIDR, TOP6BL, and RAD51AP2 in families 1, 2, and 3, respectively. Segregation in individual families revealed that the parents were carriers, as were the fertile siblings in families 1 and 2. All three genes function in double-strand break formation or repair, identified variants may therefore impair, potentially preventing its completion and contributing to infertility in the index cases. Gene-disease relationships (GDR) were re-evaluated due to the addition of new patients and/or variants in the literature. Conclusion Our findings provide additional evidence for the role of SPIDR, TOP6BL, and RAD51AP2 as genetic contributors to human infertility due to meiotic errors. For patients with a similar phenotype, genetic screening could be recommended, and the identification of pathogenic variations might help avoid unsuccessful fertility treatments. Additionally, in patients with molecular defects in DNA repair genes, chromosomal instability may increase the risk of cancer; therefore, long-term follow-up by a multidisciplinary team is recommended.
- 5 February 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (4) , 1209-1218
Disruption of meiotic double-strand break dynamics provokes germline human infertility in both sexes
Purpose To explore genetic basis leading to meiotic disruption in human gametogenesis via exome sequencing. Methods This study included three consanguineous families with well-defined infertility phenotypes. Exome sequencing was performed for the index case in family 1 and for the trio (index with parents) in the other two families. Sanger sequencing was used for confirmation and family segregation analysis. Results Exome sequencing revealed homozygous loss-of-function variations in SPIDR, TOP6BL, and RAD51AP2 in families 1, 2, and 3, respectively. Segregation in individual families revealed that the parents were carriers, as were the fertile siblings in families 1 and 2. All three genes function in double-strand break formation or repair, identified variants may therefore impair, potentially preventing its completion and contributing to infertility in the index cases. Gene-disease relationships (GDR) were re-evaluated due to the addition of new patients and/or variants in the literature. Conclusion Our findings provide additional evidence for the role of SPIDR, TOP6BL, and RAD51AP2 as genetic contributors to human infertility due to meiotic errors. For patients with a similar phenotype, genetic screening could be recommended, and the identification of pathogenic variations might help avoid unsuccessful fertility treatments. Additionally, in patients with molecular defects in DNA repair genes, chromosomal instability may increase the risk of cancer; therefore, long-term follow-up by a multidisciplinary team is recommended.
- Open Access
- 19 May 2025
- Published by Springer Nature in Reproductive Sciences
- p. 1
Correction: Evaluation of an Updated Gene Panel as a Diagnostic Tool for Both Male and Female Infertility
- 19 May 2025
- Published by Springer Nature in Reproductive Sciences
- p. 1
Open AccessCorrection: Evaluation of an Updated Gene Panel as a Diagnostic Tool for Both Male and Female Infertility
- 25 April 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (8) , 2309-2317
Evaluation of an Updated Gene Panel as a Diagnostic Tool for Both Male and Female Infertility
In recent years, an increasing number of genes associated with male and female infertility have been identified. The genetics of infertility is no longer limited to the analysis of karyotypes or specific genes, and it is now possible to analyse several dozen infertility genes simultaneously. Here, we present the diagnostic activity over the past two years including 140 patients (63 women and 77 men). Targeted sequencing revealed causative variants in 17 patients, representing an overall diagnostic rate of 12.1%, with prevalence rates in females and males of 11% and 13%, respectively. The gene-disease relationship (GDR) was re-evaluated for genes due to the addition of new patients and/or variants in the actual study. Five genes changed categories: two female genes (MEIOB and TBPL2) moved from limited to moderate; two male genes (SOHLH1 and GALNTL5) moved from no evidence to strong and from limited to moderate; and SEPTIN12, which was unable to classify male infertility, was reclassified as limited. Many infertility genes have yet to be identified. With the increasing integration of genetics in reproductive medicine, the scope of intervention extends to include other family members, in addition to individual patients or couples. Genetic counselling consultations and appropriate staffing will need to be established in fertility centres. Trial registration number: Not applicable.
- 25 April 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (8) , 2309-2317
Evaluation of an Updated Gene Panel as a Diagnostic Tool for Both Male and Female Infertility
In recent years, an increasing number of genes associated with male and female infertility have been identified. The genetics of infertility is no longer limited to the analysis of karyotypes or specific genes, and it is now possible to analyse several dozen infertility genes simultaneously. Here, we present the diagnostic activity over the past two years including 140 patients (63 women and 77 men). Targeted sequencing revealed causative variants in 17 patients, representing an overall diagnostic rate of 12.1%, with prevalence rates in females and males of 11% and 13%, respectively. The gene-disease relationship (GDR) was re-evaluated for genes due to the addition of new patients and/or variants in the actual study. Five genes changed categories: two female genes (MEIOB and TBPL2) moved from limited to moderate; two male genes (SOHLH1 and GALNTL5) moved from no evidence to strong and from limited to moderate; and SEPTIN12, which was unable to classify male infertility, was reclassified as limited. Many infertility genes have yet to be identified. With the increasing integration of genetics in reproductive medicine, the scope of intervention extends to include other family members, in addition to individual patients or couples. Genetic counselling consultations and appropriate staffing will need to be established in fertility centres. Trial registration number: Not applicable.
- 5 October 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (12) , 2289-2295
Genetics of infertility: a paradigm shift for medically assisted reproduction
The field of reproductive genetics has undergone significant advancements with the completion of the Human Genome Project and the development of high-throughput sequencing techniques. This has led to the identification of numerous genes involved in both male and female infertility, revolutionizing the diagnosis and management of infertility patients. Genetic investigations, including karyotyping, specific genetic tests, and high-throughput sequencing, have become essential in determining the genetic causes of infertility. Moreover, the integration of genetics into reproductive medicine has expanded the scope of care to include not only affected individuals or couples but also their family members. Genetic consultations and counselling play a crucial role in identifying potentially affected relatives and offering tailored therapy and the possibility of fertility preservation. Despite the current limited therapeutic options, an increasing understanding of genotype–phenotype correlations in infertility genes holds promise for improved treatment outcomes. The availability of genetic diagnostic tools has reduced the number of idiopathic infertility cases by providing accurate aetiological diagnoses. The transition from research to clinical practice in reproductive genetics requires the establishment of genetic consultations and data warehousing systems to provide up-to-date information on gene–disease relationships. Overall, the integration of genetics into reproductive medicine has brought about a paradigm shift, emphasizing the familial dimension of infertility and offering new possibilities for personalized care and family planning.
- 5 October 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (12) , 2289-2295
Genetics of infertility: a paradigm shift for medically assisted reproduction
The field of reproductive genetics has undergone significant advancements with the completion of the Human Genome Project and the development of high-throughput sequencing techniques. This has led to the identification of numerous genes involved in both male and female infertility, revolutionizing the diagnosis and management of infertility patients. Genetic investigations, including karyotyping, specific genetic tests, and high-throughput sequencing, have become essential in determining the genetic causes of infertility. Moreover, the integration of genetics into reproductive medicine has expanded the scope of care to include not only affected individuals or couples but also their family members. Genetic consultations and counselling play a crucial role in identifying potentially affected relatives and offering tailored therapy and the possibility of fertility preservation. Despite the current limited therapeutic options, an increasing understanding of genotype–phenotype correlations in infertility genes holds promise for improved treatment outcomes. The availability of genetic diagnostic tools has reduced the number of idiopathic infertility cases by providing accurate aetiological diagnoses. The transition from research to clinical practice in reproductive genetics requires the establishment of genetic consultations and data warehousing systems to provide up-to-date information on gene–disease relationships. Overall, the integration of genetics into reproductive medicine has brought about a paradigm shift, emphasizing the familial dimension of infertility and offering new possibilities for personalized care and family planning.
- Open Access
- 1 June 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (Supplement)
P-714 Clinical utility of FMR1 screening: risk factor or monogenic cause for POI
Is there a risk factor association or a monogenic relationship between FMR1 premutation and developing Fragile X-associated primary ovarian insufficiency (FXPOI)? There is an association between FMR1 premutation and FXPOI rather than a monogenic relationship, which is highly dependent on ethnicity. Among the 40 genes involved in primary ovarian insufficiency (POI), identified in our recent systematic review (Van Der Kelen et al., 2022), the FMR1 premutation is considered as the most common cause of POI. A premutation in the FMR1 gene is defined as a CGG trinucleotide repeat length between 55 and 200 in the 5′ untranslated region. The term FXPOI is used for women with premutation in FMR1 who have a loss of normal function of the ovaries before the age of 40. There is conflicting evidence about the relationship between POI and length of premutation FMR1 alleles. Curated publications identified in PubMed and Web of Science on genetics of human female infertility and sex development by using the MESH terms, key words and inclusion/exclusion criteria described in our comprehensive systematic review were subjected to screening for “FMR1 gene.” The articles included cover a period from 1988 to the 1st of November 2021. A total of 161 publications in PubMed and 61 unique publications in Web of Science were identified, and subsequently screened for triplet expansion, primary ovarian insufficiency, and/or early menopause. Of these, 56 papers were selected, excluding publications exclusively on males as well as studies on non-human species, pediatric cases, reviews, and expression studies. The study and control groups repeat numbers, ethnicity, and conclusions in the article are listed. Expansion in CGG trinucleotide repeat length happens at female meiosis and the risk for expansion increases with an increasing number of CGG repeats. There is an intermediate zone between 45 and 55 CGG repeats when the allele may be stable or unstable. Among 56 publications, 54 describing FMR1 triplet repeat size in women with POI, 34 were studying only the women with POI (observational) while 20 were including also control group (comparative). 2 publications were meta-analyses in which 13 and 11 case control studies were included respectively, 5 studies being in common. POI-associated premutations showed a wide range of repeat sizes. Women carrying midsize range repeats (>70-<100) potentially have a higher risk for POI compared to the general population. In recent decades, population-based screenings have indicated that FMR1 premutations are not as prevalent in women with ovarian insufficiency as previous estimates have suggested, but they still represent a substantial cause of POI. When present, the number of AGG interruptions and the size of uninterrupted CGG repeats are directly correlated with the ovarian reserve. No increased risk of POI associated with a premutation was reported among populations of non-European descent, such as the Han Chinese, Indian, and Jordan populations. Available reports are difficult to compare because the ethnicity and number of patients analyzed, availability of clinical data and the quality of results are different in each study. Additionally, an effect of X-inactivation in POI women with premutation was not studied. Owing to the low penetrance and a molecular mechanism that has not yet been fully elucidated, the clinical utility of FMR1 screening in women with reduced ovarian reserve needs further investigation before clinical implication. N/A
- 1 June 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (Supplement)
Open AccessP-714 Clinical utility of FMR1 screening: risk factor or monogenic cause for POI
Is there a risk factor association or a monogenic relationship between FMR1 premutation and developing Fragile X-associated primary ovarian insufficiency (FXPOI)? There is an association between FMR1 premutation and FXPOI rather than a monogenic relationship, which is highly dependent on ethnicity. Among the 40 genes involved in primary ovarian insufficiency (POI), identified in our recent systematic review (Van Der Kelen et al., 2022), the FMR1 premutation is considered as the most common cause of POI. A premutation in the FMR1 gene is defined as a CGG trinucleotide repeat length between 55 and 200 in the 5′ untranslated region. The term FXPOI is used for women with premutation in FMR1 who have a loss of normal function of the ovaries before the age of 40. There is conflicting evidence about the relationship between POI and length of premutation FMR1 alleles. Curated publications identified in PubMed and Web of Science on genetics of human female infertility and sex development by using the MESH terms, key words and inclusion/exclusion criteria described in our comprehensive systematic review were subjected to screening for “FMR1 gene.” The articles included cover a period from 1988 to the 1st of November 2021. A total of 161 publications in PubMed and 61 unique publications in Web of Science were identified, and subsequently screened for triplet expansion, primary ovarian insufficiency, and/or early menopause. Of these, 56 papers were selected, excluding publications exclusively on males as well as studies on non-human species, pediatric cases, reviews, and expression studies. The study and control groups repeat numbers, ethnicity, and conclusions in the article are listed. Expansion in CGG trinucleotide repeat length happens at female meiosis and the risk for expansion increases with an increasing number of CGG repeats. There is an intermediate zone between 45 and 55 CGG repeats when the allele may be stable or unstable. Among 56 publications, 54 describing FMR1 triplet repeat size in women with POI, 34 were studying only the women with POI (observational) while 20 were including also control group (comparative). 2 publications were meta-analyses in which 13 and 11 case control studies were included respectively, 5 studies being in common. POI-associated premutations showed a wide range of repeat sizes. Women carrying midsize range repeats (>70-<100) potentially have a higher risk for POI compared to the general population. In recent decades, population-based screenings have indicated that FMR1 premutations are not as prevalent in women with ovarian insufficiency as previous estimates have suggested, but they still represent a substantial cause of POI. When present, the number of AGG interruptions and the size of uninterrupted CGG repeats are directly correlated with the ovarian reserve. No increased risk of POI associated with a premutation was reported among populations of non-European descent, such as the Han Chinese, Indian, and Jordan populations. Available reports are difficult to compare because the ethnicity and number of patients analyzed, availability of clinical data and the quality of results are different in each study. Additionally, an effect of X-inactivation in POI women with premutation was not studied. Owing to the low penetrance and a molecular mechanism that has not yet been fully elucidated, the clinical utility of FMR1 screening in women with reduced ovarian reserve needs further investigation before clinical implication. N/A
- 26 December 2022
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 29 (2) , 218-232
A systematic review and evidence assessment of monogenic gene–disease relationships in human female infertility and differences in sex development
As in other domains of medicine, high-throughput sequencing methods have led to the identification of an ever-increasing number of gene variants in the fields of both male and female infertility. The increasing number of recently identified genes allows an accurate diagnosis for previously idiopathic cases of female infertility and more appropriate patient care. However, robust evidence of the gene–disease relationships (GDR) allowing the proper translation to clinical application is still missing in many cases. An evidence-based curation of currently identified genes involved in female infertility and differences in sex development (DSD) would significantly improve both diagnostic performance and genetic research. We therefore performed a systematic review to summarize current knowledge and assess the available GDR. PRISMA guidelines were applied to curate all available information from PubMed and Web of Science on genetics of human female infertility and DSD leading to infertility, from 1 January 1988 to 1 November 2021. The reviewed pathologies include non-syndromic as well as syndromic female infertility, and endocrine and reproductive system disorders. The evidence that an identified phenotype is caused by pathogenic variants in a specific gene was assessed according to a standardized scoring system. A final score (no evidence, limited, moderate, strong, or definitive) was assigned to every GDR. A total of 45 271 publications were identified and screened for inclusion of which 1078 were selected for gene and variant extraction. We have identified 395 genes and validated 466 GDRs covering all reported monogenic causes of female infertility and DSD. Furthermore, we present a genetic diagnostic flowchart including 105 genes with at least moderate evidence for female infertility and suggest recommendations for future research. The study did not take into account associated genetic risk factor(s) or oligogenic/polygenic causes of female infertility. We have comprehensively reviewed the existing research on the genetics of female infertility and DSD, which will enable the development of diagnostic panels using validated genes. Whole genome analysis is shifting from predominantly research to clinical application, increasing its diagnostic potential. These new diagnostic possibilities will not only decrease the number of idiopathic cases but will also render genetic counselling more effective for infertile patients and their families. Current evidence supports using 105 genes in panels to screen for female infertility and differences in sex development.
- 26 December 2022
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 29 (2) , 218-232
A systematic review and evidence assessment of monogenic gene–disease relationships in human female infertility and differences in sex development
As in other domains of medicine, high-throughput sequencing methods have led to the identification of an ever-increasing number of gene variants in the fields of both male and female infertility. The increasing number of recently identified genes allows an accurate diagnosis for previously idiopathic cases of female infertility and more appropriate patient care. However, robust evidence of the gene–disease relationships (GDR) allowing the proper translation to clinical application is still missing in many cases. An evidence-based curation of currently identified genes involved in female infertility and differences in sex development (DSD) would significantly improve both diagnostic performance and genetic research. We therefore performed a systematic review to summarize current knowledge and assess the available GDR. PRISMA guidelines were applied to curate all available information from PubMed and Web of Science on genetics of human female infertility and DSD leading to infertility, from 1 January 1988 to 1 November 2021. The reviewed pathologies include non-syndromic as well as syndromic female infertility, and endocrine and reproductive system disorders. The evidence that an identified phenotype is caused by pathogenic variants in a specific gene was assessed according to a standardized scoring system. A final score (no evidence, limited, moderate, strong, or definitive) was assigned to every GDR. A total of 45 271 publications were identified and screened for inclusion of which 1078 were selected for gene and variant extraction. We have identified 395 genes and validated 466 GDRs covering all reported monogenic causes of female infertility and DSD. Furthermore, we present a genetic diagnostic flowchart including 105 genes with at least moderate evidence for female infertility and suggest recommendations for future research. The study did not take into account associated genetic risk factor(s) or oligogenic/polygenic causes of female infertility. We have comprehensively reviewed the existing research on the genetics of female infertility and DSD, which will enable the development of diagnostic panels using validated genes. Whole genome analysis is shifting from predominantly research to clinical application, increasing its diagnostic potential. These new diagnostic possibilities will not only decrease the number of idiopathic cases but will also render genetic counselling more effective for infertile patients and their families. Current evidence supports using 105 genes in panels to screen for female infertility and differences in sex development.
- 16 December 2022
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (2) , 306-314
A biallelic loss of function variant in HORMAD1 within a large consanguineous Turkish family is associated with spermatogenic arrest
Can the analysis of a large Turkish consanguineous family via whole exome sequencing (WES) identify novel causative genetic variation responsible for nonobstructive azoospermia (NOA) characterized by arrest at primary spermatocyte stage? WES analysis revealed a homozygous nonsense variant in HORMAD1 in three affected brothers of a Turkish family. Studying patient cohorts in small or large consanguineous families using high-throughput sequencing allows the identification of genetic causes of different pathologies, including infertility. Over the last two decades, a number of genes involved in human male infertility have been discovered, but only 14 genes have been identified as being at least moderately linked to isolated NOA or oligozoospermia in men. The study included a Turkish family comprising three brothers with NOA. Two brothers had a normal karyotype, normal hormonal levels and no Yq microdeletion. The testicular histopathology analysis revealed the complete arrest of spermatogenesis at the primary spermatocyte stage. We recruited a consanguineous Turkish family where parents were first-degree cousins and had seven children; three sons who had NOA, two sons who were fertile and two daughters for whom no information was available. Saliva samples from the index patient, his two affected brothers, parents and two nonaffected brothers (seven samples in total) were collected. Prior to WES, the index patient underwent targeted genetic testing using an infertility panel, which includes 133 infertility genes. No pathogenic variations were identified. WES was then performed on the DNA of the seven family members available. Bioinformatics analysis was performed using an in-house pipeline. Detected variants were scored and ranked, and copy number variants were called and annotated. The consequences of mutation on protein expression and localization were investigated by cell transfection followed by immunofluorescence or immunoblotting. WES revealed a homozygous nonsense variant chr1:150675797G>A; HORMAD1 (NM_032132.5): c.1021C>T, p.Gln341* in exon 13, which was confirmed in all three affected brothers. HORMAD1 encodes the HORMA domain-containing protein 1. The parents as well as the two fertile brothers were carriers of this variant. This variant may lead to the production of a truncated protein lacking the nuclear localization signal; therefore, human cells were transfected with the wild-type and mutated form, in fusion with green fluorescent protein. Immunoblotting experiments confirmed the production of a truncated HORMAD1 protein, and immunofluorescence microscopy revealed that the mutated protein displayed cytoplasmic localization while the wild type protein located to the nucleus. Altogether, our findings validate HORMAD1 as an essential genetic factor in the meiotic process in human. According to one scoring system used to evaluate the clinical validity of male infertility genes, this study would classify HORMAD1 as displaying limited clinical evidence of being involved in male infertility. However, such a score is the maximum possible when only one family is analyzed and the addition of one patient showing a pathogenic or likely pathogenic variant would immediately change this classification to ‘moderate’. Thus, this report should prompt other researchers to screen patients with NOA for this genetic variant. Identification of new genetic factors involved in the human meiosis process will contribute to an improvement of our knowledge at the basic level, which in turn will allow the management of better care for infertile patients. Since Hormad1−/− knock-out female mice are also infertile, HORMAD1 could also be involved in human female infertility. Our findings have direct implications for the genetic counseling of patients and their family members. The study was funded by Fondation Maladies Rares (High Throughput Sequencing and Rare Diseases—2018, ‘GenOmics of rare diseases’). The authors declare that they have no conflict of interest. N/A.
- 16 December 2022
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (2) , 306-314
A biallelic loss of function variant in HORMAD1 within a large consanguineous Turkish family is associated with spermatogenic arrest
Can the analysis of a large Turkish consanguineous family via whole exome sequencing (WES) identify novel causative genetic variation responsible for nonobstructive azoospermia (NOA) characterized by arrest at primary spermatocyte stage? WES analysis revealed a homozygous nonsense variant in HORMAD1 in three affected brothers of a Turkish family. Studying patient cohorts in small or large consanguineous families using high-throughput sequencing allows the identification of genetic causes of different pathologies, including infertility. Over the last two decades, a number of genes involved in human male infertility have been discovered, but only 14 genes have been identified as being at least moderately linked to isolated NOA or oligozoospermia in men. The study included a Turkish family comprising three brothers with NOA. Two brothers had a normal karyotype, normal hormonal levels and no Yq microdeletion. The testicular histopathology analysis revealed the complete arrest of spermatogenesis at the primary spermatocyte stage. We recruited a consanguineous Turkish family where parents were first-degree cousins and had seven children; three sons who had NOA, two sons who were fertile and two daughters for whom no information was available. Saliva samples from the index patient, his two affected brothers, parents and two nonaffected brothers (seven samples in total) were collected. Prior to WES, the index patient underwent targeted genetic testing using an infertility panel, which includes 133 infertility genes. No pathogenic variations were identified. WES was then performed on the DNA of the seven family members available. Bioinformatics analysis was performed using an in-house pipeline. Detected variants were scored and ranked, and copy number variants were called and annotated. The consequences of mutation on protein expression and localization were investigated by cell transfection followed by immunofluorescence or immunoblotting. WES revealed a homozygous nonsense variant chr1:150675797G>A; HORMAD1 (NM_032132.5): c.1021C>T, p.Gln341* in exon 13, which was confirmed in all three affected brothers. HORMAD1 encodes the HORMA domain-containing protein 1. The parents as well as the two fertile brothers were carriers of this variant. This variant may lead to the production of a truncated protein lacking the nuclear localization signal; therefore, human cells were transfected with the wild-type and mutated form, in fusion with green fluorescent protein. Immunoblotting experiments confirmed the production of a truncated HORMAD1 protein, and immunofluorescence microscopy revealed that the mutated protein displayed cytoplasmic localization while the wild type protein located to the nucleus. Altogether, our findings validate HORMAD1 as an essential genetic factor in the meiotic process in human. According to one scoring system used to evaluate the clinical validity of male infertility genes, this study would classify HORMAD1 as displaying limited clinical evidence of being involved in male infertility. However, such a score is the maximum possible when only one family is analyzed and the addition of one patient showing a pathogenic or likely pathogenic variant would immediately change this classification to ‘moderate’. Thus, this report should prompt other researchers to screen patients with NOA for this genetic variant. Identification of new genetic factors involved in the human meiosis process will contribute to an improvement of our knowledge at the basic level, which in turn will allow the management of better care for infertile patients. Since Hormad1−/− knock-out female mice are also infertile, HORMAD1 could also be involved in human female infertility. Our findings have direct implications for the genetic counseling of patients and their family members. The study was funded by Fondation Maladies Rares (High Throughput Sequencing and Rare Diseases—2018, ‘GenOmics of rare diseases’). The authors declare that they have no conflict of interest. N/A.